Characterisation of Potential Antidiabetic-Related Proteins from Pleurotus pulmonarius (Fr.) Quél. (Grey Oyster Mushroom) by MALDI-TOF/TOF Mass Spectrometry

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Wahab, Nurul Azwa Abd ^a   Abdullah, Noorlidah ^a   Aminudin, Norhaniza ^a,b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMYLASE PANCREAS ISOENZYME; ALPHA GLUCOSIDASE; AMMONIUM SULFATE; ANTIDIABETIC AGENT; CATALASE LIKE PROTEIN; FUNGAL ENZYME; FUNGAL EXTRACT; FUNGAL PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE LIKE PROTEIN; PROFILIN LIKE PROTEIN; TREHALOSE PHOSPHORYLASE LIKE PROTEIN; UNCLASSIFIED DRUG; AMYLASE;

ANTIDIABETIC ACTIVITY; ARTICLE; ENZYME ACTIVITY; FRACTIONATION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PLEUROTUS PULMONARIUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN PURIFICATION; REGULATORY MECHANISM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SACCHAROMYCES CEREVISIAE; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PLEUROTUS; PROCEDURES; REVERSED PHASE LIQUID CHROMATOGRAPHY; SILVER STAINING;

PLEUROTUS OSTREATUS; PLEUROTUS PULMONARIUS; SACCHAROMYCES CEREVISIAE; SUS;

ALPHA-AMYLASES; ALPHA-GLUCOSIDASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FUNGAL PROTEINS; HYPOGLYCEMIC AGENTS; PLEUROTUS; SILVER STAINING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84934958113     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/131607     Document Type: Article

References (55)

1. L. Li, Z. Wang, X. Ying et al., "Garlic for diabetes mellitus, " Cochrane Database of Systematic Reviews, no. 7, Article ID CD009981, 2012.
2. C. Sanz, J.-F.. Gautier, and H. Hanaire, "Physical exercise for the prevention and treatment of type 2 diabetes, " Diabetes and Metabolism, vol. 36, no. 5, pp. 346-351, 2010.
3. S. Maggi, M. Noale, A. Pilotto, A. Tiengo, P. Cavallo Perin, and G. Crepaldi, "The Metabolic Study: A multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment, " Diabetes and Metabolism, vol. 39, no. 3, pp. 236-243, 2013.
4. A. Hussain, B. Claussen, A. Ramachandran, and R. Williams, "Prevention of type 2 diabetes: A review, " Diabetes Research and Clinical Practice, vol. 76, no. 3, pp. 317-326, 2007.
5. S. Genuth, K. G. Alberti, P. Bennett et al., "Follow-up report on the diagnosis of diabetes mellitus, " Diabetes Care, vol. 26, no. 11, pp. 3160-3167, 2003.
6. M. I. Ortiz, H. A. Ponce-Monter, E. Fernánd ez-Martínez et al., "Pharmacological interaction between gabapentin and glibenclamide in the formalin test in the diabetic rat, " Proceedings of the Western Pharmacology Society, vol. 53, pp. 49-51, 2010.
7. S. K. Singh, P. K. Rai, D. Jaiswal, and G.Watal, "Evidence-based critical evaluation of glycemic potential of Cynodon dactylon, " Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 4, pp. 415-420, 2008.
8. N. Malviya, S. Jain, and S. Malviya, "Antidiabetic potential of medicinal plants, " Acta Poloniae Pharmaceutica, vol. 67, no. 2, pp. 113-118, 2010.
9. U. Etxeberria, A. L. de La Garza, J. Campin, J. A. Martnez, and F. I. Milagro, "Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase, " Expert Opinion on Therapeutic Targets, vol. 16, no. 3, pp. 269-297, 2012.
10. R. Aebersold and M. Mann, "Mass spectrometry-based proteomics, " Nature, vol. 422, no. 6928, pp. 198-207, 2003.
11. T. B. Ng, "Peptides and proteins from fungi, " Peptides, vol. 25, no. 6, pp. 1055-1073, 2004.
12. L. Chen, B. Zhang, and P. C. K. Cheung, "Comparative proteomic analysis of mushroom cell wall proteins among the different developmental stages of Pleurotus tuber-regium, " Journal of Agricultural and Food Chemistry, vol. 60, no. 24, pp. 6173-6182, 2012.
13. M. A. Khan and M. Tania, "Nutritional and medicinal importance of Pleurotus mushrooms: A n overview, " Food Reviews International, vol. 28, no. 3, pp. 313-329, 2012.
14. Y. H. Tan and M. N.Wahab, "Extracellular enzyme production during anamorphic growth in the edible mushroom, Pleurotus sajor-caju, " World Journal of Microbiology and Biotechnology, vol. 13, no. 6, pp. 613-617, 1997.
15. R. P. Agrawal, A. Chopra, G. S. Lavekar et al., "Effect of oyster mushroom on glycemia, lipid profile and quality of life in type 2 diabetic patients, " Australian Journal of Medical Herbalism, vol. 22, no. 2, pp. 50-54, 2010.
16. M. Pramanik, S. Mondal, I. Chakraborty, D. Rout, and S. S. Islam, "Structural investigation of a polysaccharide (Fr. II) isolated from the aqueous extract of an edible mushroom, Pleurotus sajor-caju, " Carbohydrate Research, vol. 340, no. 4, pp. 629-636, 2005.
17. S. T. Chang and P. G.Miles, Mushrooms; Cultivation, Nutritional Value, Medicinal Effect, and Environmental Impact, CRC Press, New York, NY, USA, 2004.
18. C. Ying, Y.Wang, and H. Tang, "Fungi-medicine-Chinese- identification-therapeutic use-pictorial works-China, " in Icons of Medicinal Fungi from China, pp. 572-575, 1987.
19. E. Apostolidis, Y. I. Kwon, and K. Shetty, "Potential of cranberry-based herbal synergies for diabetes and hypertension management, " Asia Pacific Journal of Clinical Nutrition, vol. 15, no. 3, pp. 433-441, 2006.
20. E. Apostolidis, Y.-I. Kwon, and K. Shetty, "Inhibitory potential of herb, fruit, and fungal-enriched cheese against key enzymes linked to type 2 diabetes and hypertension, " Innovative Food Science & Emerging Technologies, vol. 8, no. 1, pp. 46-54, 2007.
21. U. Laemmli, "SDS-PAGE to evaluate extent of hydrolysis, of proteins, " Nature, vol. 227, no. 5259, pp. 680-685, 1976.
22. R. A. Codario, "Oral agents for type-2 diabetes, " in Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome, Current Clinical Practice, pp. 93-122, Humana Press, 2011.
23. G. Kanagasabapathy, S. N. A. Malek, A. A. Mahmood, K. H. Chua, S. Vikineswary, and U. R.Kuppusamy, "Beta-glucan-rich extract from Pleurotus sajor-caju (Fr.) singer prevents obesity and oxidative stress in C57BL/6J mice fed on a high-fat diet, " Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 185259, 10 pages, 2013.
24. R. K. Scopes, Protein Purification: A Principles and Practice, Springer, NewYork, NY, USA, 3rd edition, 1994.
25. N. Seedher and M. Kanojia, "Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin, " Chemical Biology and Drug Design, vol. 72, no. 4, pp. 290-296, 2008.
26. A. Meland er, "Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: A brief overview, " Diabetes, vol. 53, supplemement 3, pp. S151-S155, 2004.
27. A. Gruzman, G. Babai, S. Sasson et al., "Erratum to: A adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: A review on metabolic, pharmacological and chemical considerations by gruzman et al., rev diabet stud 2009, 6 (1): A 13-36, " The Review of Diabetic Studies: A RDS, vol. 6, no. 2, article 130, 2009.
28. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. and reelli, "Cellular and molecular mechanisms of metformin: A n overview, " Clinical Science, vol. 122, no. 6, pp. 253-270, 2012.
29. N. G. Oikonomakos, S. E. Zographos, V. T. Skamnaki, and G. Archontis, "The 1.76 ?A resolution crystal structure of glycogen phosphorylase B complexed with glucose, and CP320626, a potential antidiabetic drug, " Bioorganic &Medicinal Chemistry, vol. 10, no. 5, pp. 1313-1319, 2002.
30. K. H.Thompson and C. Orvig, "Vanadiumin diabetes: A 100 years from Phase 0 to Phase I, " Journal of Inorganic Biochemistry, vol. 100, no. 12, pp. 1925-1935, 2006.
31. L. Vidali, R. C. Augustine, K. P. Kleinman, and M. Bezanilla, "Profilin is essential for tip growth in the moss Physcomitrella patens, " The Plant Cell, vol. 19, no. 11, pp. 3705-3722, 2007.
32. L. Y. Chu and R. L. Silverstein, "CD36 ectodomain phosphorylation blocks thrombospondin-1 binding structure-function relationships and regulation by protein kinase C, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 3, pp. 760-767, 2012.
33. P. Geraldes and G. L. King, "Activation of protein kinase C isoforms and its impact on diabetic complications, " Circulation Research, vol. 106, no. 8, pp. 1319-1331, 2010.
34. L. Piconi, M. A. Ihnat, and A. Ceriello, "Oxidative stress in the pathogenesis/treament of diabetes and its complications, " Current Nutrition and Food Science, vol. 3, no. 3, pp. 194-199, 2007.
35. M. T. Elnakish and H. H. Hassanain, "Profilin, and vascular diseases, " in Biochemistry, pp. 65-106, InTech, Rijeka, Croatia, 2012.
36. J. Menne, M. Meier, J. Park, and H. Haller, "Inhibition of protein kinaseCin diabetic nephropathy-where dowe stand ? Nephrology Dialysis Transplantation, vol. 24, no. 7, pp. 2021-2023, 2009.
37. I. Skvortsova, "Profilin 1: A do we have a novel proteomefound biomarker predicting response to anticancer therapy? Proteomics, vol. 13, no. 14, pp. 2069-2071, 2013.
38. D. L. V. Jagt, "Methylglyoxal, diabetes mellitus and diabetic complications, " Drug Metabolism and Drug Interactions, vol. 23, no. 1-2, pp. 93-124, 2008.
39. S.Madsen-Bouterse, G.Mohammad, and R. A. Kowluru, "Glyceraldehyde- 3-phosphate dehydrogenase in retinal microvasculature: A implications for the development and progression of diabetic retinopathy, " Investigative Ophthalmology and Visual Science, vol. 51, no. 3, pp. 1765-1772, 2010.
40. M. Brownlee, "The pathobiology of diabetic complications: A unifying mechanism, " Diabetes, vol. 54, no. 6, pp. 1615-1625, 2005.
41. P.Maher, "Methylglyoxal, advanced glycation end products and autism: A is there a connection? Medical Hypotheses, vol. 78, no. 4, pp. 548-552, 2012.
42. P. J. Beisswenger, S. K. Howell, K. Smith, and B. S. Szwergold, "Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes, " Biochimica et Biophysica Acta: A Molecular Basis of Disease, vol. 1637, no. 1, pp. 98-106, 2003.
43. A. D. Elbein, Y. T. Pan, I. Pastuszak, and D. Carroll, "New insights on trehalose: A amultifunctionalmolecule, " Glycobiology, vol. 13, no. 4, pp. 17R-27R, 2003.
44. C. Eis and B. Nidetzky, "Characterization of trehalose phosphorylase fromSchizophyllumcommune, " Biochemical Journal, vol. 341, no. 2, pp. 385-393, 1999.
45. C. Arai, M. Kohguchi, S. Akamatsu et al., "Trehalose suppresses lipopolysaccharide-induced osteoclastogenesis bone marrow in mice, " Nutrition Research, vol. 21, no. 7, pp. 993-999, 2001.
46. C. Arai, N. Arai, A. Mizote et al., "Trehalose prevents adipocyte hypertrophy and mitigates insulin resistance, " Nutrition Research, vol. 30, no. 12, pp. 840-848, 2010.
47. Y. Pan, J. D. Carroll, N. Asano, I. Pastuszak, V. K. Edavana, and A. D. Elbein, "Trehalose synthase converts glycogen to trehalose, " Federation of European Biochemical Societies Journal, vol. 275, no. 13, pp. 3408-3420, 2008.
48. A. Wolf, R. Krämer, and S. Morbach, "Three pathways for trehalose metabolism in Corynebacterium glutamicum ATCC13032 and their significance in response to osmotic stress, " Molecular Microbiology, vol. 49, no. 4, pp. 1119-1134, 2003.
49. L. Góth and W. N. Bigler, "Blood catalase deficiency and diabetes in Hungary, " Diabetes Care, vol. 24, no. 10, pp. 1839-1840, 2001.
50. J. Styskal, H. van Remmen, A. Richardson, and A. B. Salmon, "Oxidative stress and diabetes: A what can we learn about insulin resistance from antioxidant mutant mouse models? Free Radical Biology and Medicine, vol. 52, no. 1, pp. 46-58, 2012.
51. L. Góth and T. Nagy, "Acatalasemia and diabetes mellitus, " Archives of Biochemistry and Biophysics, vol. 525, no. 2, pp. 195-200, 2012.
52. M. Prentki and C. J.Nolan, "Islet β cell failure in type 2 diabetes, " The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1802-1812, 2006.
53. J. W. Baynes and S. R. Thorpe, "Role of oxidative stress in diabetic complications: A new perspective on an old paradigm, " Diabetes, vol. 48, no. 1, pp. 1-9, 1999.
54. S. B. Bankar, M. V. Bule, R. S. Singhal, and L. Ananthanarayan, "Optimization of Aspergillus niger fermentation for the production of glucose oxidase, " Food and Bioprocess Technology, vol. 2, no. 4, pp. 344-352, 2009.
55. K. R. Messner and J. A. Imlay, "Mechanism of superoxide and hydrogen peroxide formation by fumarate reductase, succinate dehydrogenase, and aspartate oxidase, " The Journal of Biological Chemistry, vol. 277, no. 45, pp. 42563-42571, 2002.